基因风险对非酒精性脂肪性肝病肝纤维化的影响:基于磁共振弹性成像的评估
结果显示PNPLA3风险变异拷贝数与晚期纤维化风险及肝硬度增加相关,而HSD17B13保护性TA等位基因与肝硬度降低相关。
要点
- PNPLA3 CG和GG基因型较CC型晚期纤维化风险显著增加。
- 每增加一个PNPLA3风险变异拷贝,肝硬度增加0.40 kPa。
- HSD17B13保护性TA等位基因与肝硬度降低0.41 kPa相关。
核心结论
- PNPLA3和HSD17B13基因型知识可能有助于NAFLD的非侵入性风险分层,建议对高遗传风险者进行更密切监测。
研究设计与样本
- 横断面分析,来自一个特征明确的NAFLD风险队列,接受基因分型和磁共振弹性成像(MRE)评估。
- 晚期纤维化定义为肝硬度≥3.63千帕(kPa)。
- 使用单变量和多变量线性及逻辑回归分析评估基因型与MRE的关联。
主要发现
- 与CC PNPLA3基因型相比,CG基因型晚期纤维化比值比为3.1(95% CI:1.1-8.9,P=0.04),GG基因型为6.5(95% CI:2.2-18.9,P<0.01)。
- 在调整年龄、性别和BMI的分析中,每增加一个PNPLA3风险变异拷贝与MRE肝硬度增加0.40 kPa(95% CI:0.19-0.61,P<0.01)相关,且存在显著的基因型-年龄交互作用(P<0.01)。
- 在多变量分析中,HSD17B13保护性TA等位基因与MRE肝硬度降低0.41 kPa(95% CI:-0.76至-0.05,P=0.03)相关。
临床怎么用
- 对于NAFLD患者,可考虑检测PNPLA3和HSD17B13基因型以辅助非侵入性风险分层。
- 对携带PNPLA3高风险基因型的患者,建议更密切的监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Variants in multiple genetic loci modify the risk of non-alcoholic fatty liver disease (NAFLD) and cirrhosis but there are limited data on the quantitative impact of variant copies on liver fibrosis. AIM: To investigate the effect of PNPLA3, TM6SF2, MBOAT7, GCKR and HSD17B13 genotype on liver fibrosis assessed by magnetic resonance elastography (MRE), a reproducible, accurate, continuous biomarker of liver fibrosis. METHODS: This is a cross-sectional analysis derived from a well-characterised cohort at risk for NAFLD who underwent genotyping and MRE assessment. Liver stiffness (LS) was estimated using MRE and advanced fibrosis was defined as liver stiffness ≥3.63 kilopascals (kPa). Univariable and multivariable linear and logistic regression analysis, were used to assess the association between genotype and MRE. RESULTS: Two hundred sixty-four patients (63% women) with a mean age 53 (±17) years, and 31% Hispanic ethnicity with genotyping and MRE were included. The odds of advanced fibrosis were 3.1 (95% CI: 1.1-8.9, P = 0.04) for CG and 6.5 (95% CI: 2.2-18.9, P < 0.01) for GG compared to CC PNPLA3 genotype. Each PNPLA3 risk variant copy was associated with 0.40 kPa (95% CI: 0.19-0.61, P < 0.01) increase in LS on MRE in analysis adjusted for age, sex and BMI and there was significant genotype-age interaction (P < 0.01). Conversely, the protective TA allele in HSD17B13 was associated with a -0.41 kPa (95% CI: -0.76 to -0.05, P = 0.03) decrease in liver stiffness on MRE multivariable analysis. CONCLUSION: Knowledge of PNPLA3 and HSD17B13 genotype may assist in the non-invasive risk stratification of NAFLD with closer monitoring recommended for those with high genetic risk.
引用
- Ajmera V, Liu A, Bettencourt R, et al. The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography. Aliment Pharmacol Ther. 2021. PMID: 33975381. doi:10.1111/apt.16392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。